Tyra biosciences doses first patient with tyra-200 and provides positive updates on tyra-300

- initiated surf201 phase 1 study; dosed first patient with tyra-200-  - cleared multiple dose cohorts in surf301 and continues to dose escalate with tyra-300- - received fda feedback on tyra-300 phase 2 ach study: ind submission planned for 2h 2024- carlsbad, calif. , dec. 22, 2023 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today announced that it has initiated the surf201 phase 1 study of tyra-200 and provided positive updates on its oral fgfr3-selective inhibitor, tyra-300.
TYRA Ratings Summary
TYRA Quant Ranking